AC Immune SA ACIU

NAS: ACIU | ISIN: CH0329023102   14/11/2024
3,550 USD (+13,42%)
(+13,42%)   14/11/2024

14 november 2024 · AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease · Persbericht

13 november 2024 · AC Immune to Present at the Jefferies 2024 London Healthcare Conference · Persbericht

5 november 2024 · AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update · Persbericht

17 september 2024 · AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease · Persbericht

28 augustus 2024 · AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions · Persbericht

6 augustus 2024 · AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update · Persbericht

31 juli 2024 · AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 · Persbericht

25 juli 2024 · AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease · Persbericht

16 juli 2024 · AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 · Persbericht

28 mei 2024 · AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 · Persbericht

13 mei 2024 · AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update · Persbericht

13 mei 2024 · AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease · Persbericht

14 maart 2024 · AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update · Persbericht

22 februari 2024 · AC Immune Announces Upcoming Presentations at AD/PD™ 2024 · Persbericht

22 januari 2024 · AC Immune to Regain Global Rights to Crenezumab and Semorinemab · Persbericht

3 januari 2024 · AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases · Persbericht

15 december 2023 · AC Immune Announces Pricing of Underwritten Offering of Common Shares · Persbericht

15 december 2023 · AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial · Persbericht

1 december 2023 · AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO · Persbericht

7 november 2023 · AC Immune to Present at the Jefferies 2023 London Healthcare Conference · Persbericht

Mijn selecties